Program Description & Educational Objectives
In this activity, experts in rheumatoid arthritis discuss strategies to improve patient outcomes through appropriate initiation of therapy and monitoring of disease activity.
Upon completion of this activity, participants will be able to:
- Apply the most recent clinical data to the selection of starting agent for the treatment of RA
- Apply the most appropriate monitoring techniques to ensure consistent, tight disease control
- Initiate individualized therapy for patients with RA based on long-term safety and efficacy data as well as patient convenience
Target Audience
This activity has been designed to meet the educational needs of physicians, nurses, and other clinicians involved in the management of patients with rheumatoid arthritis.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: December 29, 2011 - December 28, 2012
Time to Complete: 45 minutes
Faculty & Disclosure / Conflict of Interest Policy
All faculty AND staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
Course Director and Interviewee
Eric M. Ruderman, MD
Professor
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Eric M. Ruderman, MD,
has a financial interest/relationship or affiliation in the form of:
Consultant for Abbott Laboratories; Amgen Inc.; CVS Caremark; Genentech, Inc.; Pfizer Inc.; Roche Laboratories Inc.; and UCB Pharma, Inc.
Grant/Research Support from Genentech, Inc.; Pfizer Inc.; and Roche Laboratories Inc.
Shareholder in The Rheumatology Education Group, LLC.
Advisory Board for Abbott Laboratories; and Eli Lilly and Company.
Interviewees
Yusuf Yazici, MD
Assistant Professor
New York University School of Medicine
NYU Hospital for Joint Diseases
New York, New York
Yusuf Yazici, MD,
has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb Company; Centocor Ortho Biotech Inc.; Celgene Corporation; Genentech, Inc.; and UCB Pharma, Inc.
Grant/Research Support from Bristol-Myers Squibb Company; Centocor Ortho Biotech Inc.; and Genentech, Inc.
Speakers Bureau participant with Bristol-Myers Squibb Company; and Genentech, Inc.
Advisory Board for Bristol-Myers Squibb Company; Centocor Ortho Biotech Inc.; Merck & Co., Inc.; and UCB Pharma, Inc.
Philip J. Mease, MD
Director of Rheumatology Research
Swedish Medical Center
Clinical Professor of Medicine
University of Washington
Seattle, Washington
Philip J. Mease, MD,
has a financial interest/relationship or affiliation in the form of:
Consultant for Abbott Laboratories; Amgen Inc.; Biogen Idec; Bristol-Myers Squibb; Celgene Corporation; Eli Lilly and Company; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and UCB Pharma, Inc.
Grant/Research Support from Abbott Laboratories; Amgen Inc.; Biogen Idec; Bristol-Myers Squibb; Celgene Corporation; Eli Lilly and Company; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and UCB Pharma, Inc.
Speakers Bureau participant with Abbott Laboratories; Amgen Inc.; Biogen Idec; Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and UCB Pharma, Inc.
Content Director
Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education
Kathryn B. Charalambous, PhD,
currently has no financial interests/relationships or affiliations in relation to this activity.
All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University College of Pharmacy staff have no relationships to disclose.
Sponsorship, Credit & Support
Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
The Purdue University College of Pharmacy designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Purdue University Continuing Nursing Education, West Lafayette, IN (ISNA No. CNEP 11-03, Exp. 06/1/2014) is an approved provider of continuing nursing education by the Indiana State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity has been approved for 0.75 contact hour(s).
Note: Not all state nursing boards will accept programs less than 1.0 hour in length for credit. Please click here to find out the status of your state.
This CME/CNE activity is jointly sponsored by Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from 
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
